SGLT2 inhibitors with conventional diuretics lower all-cause mortality in HF patients

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-01-11T11:15:12+05:30 | Updated On 13 Oct 2023 4:27 PM IST

A systematic review of nine randomized controlled trials found that the addition of SGLT2 inhibitors (SGLT2i) to conventional diuretic therapy for acute heart failure (AHF) was associated with a reduction in all-cause death and readmissions for heart failure. SGLT2i also increased daily urinary output and decreased the need for loop diuretics without worsening renal function. These findings were published in Clinical Research in Cardiology Journal.

SGLT2i are a type of medication that are commonly used to treat type 2 diabetes. However, recent research has suggested that they may also have benefits for people with heart failure. To investigate this further, a team led by Pedro Carvalho conducted a systematic review of nine randomized controlled trials involving 2,824 patients with AHF.

The study's methods involved a systematic search of three electronic databases to identify eligible trials. The primary outcome of the study was all-cause death, and secondary outcomes included readmissions for heart failure, the composite of cardiovascular death and readmissions for heart failure, daily urinary output, and the need for loop diuretics.

The findings of the study:

The addition of SGLT2i to conventional therapy for AHF reduced all-cause death (odds ratio [OR] 0.75; 95% CI 0.56–0.99; p = 0.049), readmissions for heart failure (OR 0.54; 95% CI 0.44–0.66; p < 0.001), and the composite of cardiovascular death and readmissions for heart failure (hazard ratio 0.71; 95% CI 0.60–0.84; p < 0.001).

SGLT2i also increased mean daily urinary output in liters (mean difference [MD] 0.45; 95% CI 0.03–0.87; p = 0.035) and decreased mean daily doses of loop diuretics in mg of furosemide equivalent (MD -34.90; 95% CI [− 52.58, − 17.21]; p < 0.001) without increasing the incidence of worsening renal function (OR 0.75; 95% CI 0.43–1.29; p = 0.290).

Reference:

Carvalho, P. E. P., Veiga, T. M. A., Simões e Silva, A. C., Gewehr, D. M., Dagostin, C. S., Fernandes, A., Nasi, G., & Cardoso, R. (2023). Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. In Clinical Research in Cardiology. Springer Science and Business Media LLC. https://doi.org/10.1007/s00392-022-02148-2

Clinical Research in CardiologyAcute Heart failureSGLT2 inhibitorsloop diuretics

Source : Clinical Research in Cardiology

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751